Welcome
Retrogenix has developed a powerful and innovative technology for discovering which membrane proteins are targeted by antibody, protein and small molecule drug leads. This is achieved by screening these molecules against the most comprehensive set of human plasma membrane proteins available in the context of the human cell. Covering more than 2000 proteins, this represents 65% of all known plasma membrane proteins, and we are on target to increase that to 3000 proteins (95%).
Our technology helps drug discovery companies to:
- Identify novel drug targets
- Progress or revive functional leads with unknown targets and mechanisms of action
- Avoid off-target driven toxicities
Retrogenix can provide its partners with considerable competitive advantage, by allowing them to work on unexploited drug targets and pathways. We help to improve success at all stages of the drug research and development process and reduces the huge costs associated with drug R&D.
4th October 2010
Retrogenix launches new antibody technology...
